Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?
Identifieur interne : 000161 ( Ncbi/Merge ); précédent : 000160; suivant : 000162Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?
Auteurs : C. Tranchant [France] ; C. Guiraud-Chaumeil ; A. Echaniz-Laguna ; J M WarterSource :
- Journal of neurology [ 0340-5354 ] ; 2000.
English descriptors
- KwdEn :
- MESH :
- chemical , drug effects : Growth Hormone.
- chemical : Clonidine.
- diagnosis : Multiple System Atrophy, Parkinson Disease.
- Aged, Aged, 80 and over, Diagnosis, Differential, Female, Humans, Male, Middle Aged.
Abstract
Clonidine, a centrally active alpha 2-adrenoreceptor agonist used to lower blood pressure, has been proposed to differentiate central from peripheral autonomic deficits and multiple system atrophy (MSA) from untreated idiopathic Parkinson's disease (IPD). A lack of growth hormone (GH) increase after clonidine infusion is found in patients with MSA, but not in those with IPD or with pure autonomic failure. We studied 19 IPD and 7 MSA patients to assess whether this test could be used in clinical practice to distinguish MSA from IPD, whatever the stage of the disease. Serum GH levels were measured 15, 30, 45 and 60 min after a 10-min infusion of 2 micrograms/kg clonidine. GH levels remained stable after clonidine infusion in all 7 MSA patients but increased in only 12 of the 19 IPD patients, while remaining stable in the other 7. No correlation was found with the presence of orthostatic hypotension. We conclude that the GH response to clonidine infusion has a very high sensitivity (100% in our series and in previous studies) for the diagnosis of MSA. However, this response cannot be used as a diagnostic test because of its poor specificity.
PubMed: 11151417
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001287
- to stream PubMed, to step Curation: 001246
- to stream PubMed, to step Checkpoint: 001246
Links to Exploration step
pubmed:11151417Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?</title><author><name sortKey="Tranchant, C" sort="Tranchant, C" uniqKey="Tranchant C" first="C" last="Tranchant">C. Tranchant</name><affiliation wicri:level="3"><nlm:affiliation>Service des Maladies du Système Nerveux et du Muscle, Hôpitaux Universitaires, 1 Place de l'Hôpital, 67091 Strasbourg, France. christine tranchant@chru-strasbourg.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service des Maladies du Système Nerveux et du Muscle, Hôpitaux Universitaires, 1 Place de l'Hôpital, 67091 Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Guiraud Chaumeil, C" sort="Guiraud Chaumeil, C" uniqKey="Guiraud Chaumeil C" first="C" last="Guiraud-Chaumeil">C. Guiraud-Chaumeil</name></author><author><name sortKey="Echaniz Laguna, A" sort="Echaniz Laguna, A" uniqKey="Echaniz Laguna A" first="A" last="Echaniz-Laguna">A. Echaniz-Laguna</name></author><author><name sortKey="Warter, J M" sort="Warter, J M" uniqKey="Warter J" first="J M" last="Warter">J M Warter</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:11151417</idno><idno type="pmid">11151417</idno><idno type="wicri:Area/PubMed/Corpus">001287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001287</idno><idno type="wicri:Area/PubMed/Curation">001246</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001246</idno><idno type="wicri:Area/PubMed/Checkpoint">001246</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001246</idno><idno type="wicri:Area/Ncbi/Merge">000161</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?</title><author><name sortKey="Tranchant, C" sort="Tranchant, C" uniqKey="Tranchant C" first="C" last="Tranchant">C. Tranchant</name><affiliation wicri:level="3"><nlm:affiliation>Service des Maladies du Système Nerveux et du Muscle, Hôpitaux Universitaires, 1 Place de l'Hôpital, 67091 Strasbourg, France. christine tranchant@chru-strasbourg.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service des Maladies du Système Nerveux et du Muscle, Hôpitaux Universitaires, 1 Place de l'Hôpital, 67091 Strasbourg</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Guiraud Chaumeil, C" sort="Guiraud Chaumeil, C" uniqKey="Guiraud Chaumeil C" first="C" last="Guiraud-Chaumeil">C. Guiraud-Chaumeil</name></author><author><name sortKey="Echaniz Laguna, A" sort="Echaniz Laguna, A" uniqKey="Echaniz Laguna A" first="A" last="Echaniz-Laguna">A. Echaniz-Laguna</name></author><author><name sortKey="Warter, J M" sort="Warter, J M" uniqKey="Warter J" first="J M" last="Warter">J M Warter</name></author></analytic><series><title level="j">Journal of neurology</title><idno type="ISSN">0340-5354</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Clonidine</term><term>Diagnosis, Differential</term><term>Female</term><term>Growth Hormone (drug effects)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multiple System Atrophy (diagnosis)</term><term>Parkinson Disease (diagnosis)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Growth Hormone</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Clonidine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Diagnosis, Differential</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clonidine, a centrally active alpha 2-adrenoreceptor agonist used to lower blood pressure, has been proposed to differentiate central from peripheral autonomic deficits and multiple system atrophy (MSA) from untreated idiopathic Parkinson's disease (IPD). A lack of growth hormone (GH) increase after clonidine infusion is found in patients with MSA, but not in those with IPD or with pure autonomic failure. We studied 19 IPD and 7 MSA patients to assess whether this test could be used in clinical practice to distinguish MSA from IPD, whatever the stage of the disease. Serum GH levels were measured 15, 30, 45 and 60 min after a 10-min infusion of 2 micrograms/kg clonidine. GH levels remained stable after clonidine infusion in all 7 MSA patients but increased in only 12 of the 19 IPD patients, while remaining stable in the other 7. No correlation was found with the presence of orthostatic hypotension. We conclude that the GH response to clonidine infusion has a very high sensitivity (100% in our series and in previous studies) for the diagnosis of MSA. However, this response cannot be used as a diagnostic test because of its poor specificity.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11151417</PMID><DateCreated><Year>2001</Year><Month>01</Month><Day>09</Day></DateCreated><DateCompleted><Year>2001</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-5354</ISSN><JournalIssue CitedMedium="Print"><Volume>247</Volume><Issue>11</Issue><PubDate><Year>2000</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?</ArticleTitle><Pagination><MedlinePgn>853-6</MedlinePgn></Pagination><Abstract><AbstractText>Clonidine, a centrally active alpha 2-adrenoreceptor agonist used to lower blood pressure, has been proposed to differentiate central from peripheral autonomic deficits and multiple system atrophy (MSA) from untreated idiopathic Parkinson's disease (IPD). A lack of growth hormone (GH) increase after clonidine infusion is found in patients with MSA, but not in those with IPD or with pure autonomic failure. We studied 19 IPD and 7 MSA patients to assess whether this test could be used in clinical practice to distinguish MSA from IPD, whatever the stage of the disease. Serum GH levels were measured 15, 30, 45 and 60 min after a 10-min infusion of 2 micrograms/kg clonidine. GH levels remained stable after clonidine infusion in all 7 MSA patients but increased in only 12 of the 19 IPD patients, while remaining stable in the other 7. No correlation was found with the presence of orthostatic hypotension. We conclude that the GH response to clonidine infusion has a very high sensitivity (100% in our series and in previous studies) for the diagnosis of MSA. However, this response cannot be used as a diagnostic test because of its poor specificity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tranchant</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service des Maladies du Système Nerveux et du Muscle, Hôpitaux Universitaires, 1 Place de l'Hôpital, 67091 Strasbourg, France. christine tranchant@chru-strasbourg.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guiraud-Chaumeil</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Echaniz-Laguna</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Warter</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9002-72-6</RegistryNumber><NameOfSubstance UI="D013006">Growth Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>MN3L5RMN02</RegistryNumber><NameOfSubstance UI="D003000">Clonidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol. 2002 Apr;249(4):488-9</RefSource><PMID Version="1">11967661</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003000" MajorTopicYN="Y">Clonidine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013006" MajorTopicYN="N">Growth Hormone</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>1</Month><Day>11</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>1</Month><Day>11</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11151417</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Alsace (région administrative)</li><li>Grand Est</li></region><settlement><li>Strasbourg</li></settlement></list><tree><noCountry><name sortKey="Echaniz Laguna, A" sort="Echaniz Laguna, A" uniqKey="Echaniz Laguna A" first="A" last="Echaniz-Laguna">A. Echaniz-Laguna</name><name sortKey="Guiraud Chaumeil, C" sort="Guiraud Chaumeil, C" uniqKey="Guiraud Chaumeil C" first="C" last="Guiraud-Chaumeil">C. Guiraud-Chaumeil</name><name sortKey="Warter, J M" sort="Warter, J M" uniqKey="Warter J" first="J M" last="Warter">J M Warter</name></noCountry><country name="France"><region name="Grand Est"><name sortKey="Tranchant, C" sort="Tranchant, C" uniqKey="Tranchant C" first="C" last="Tranchant">C. Tranchant</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000161 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000161 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:11151417
|texte= Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:11151417" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |